Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

βCTF-correlated burst of hippocampal TNFα occurs at a very early, pre-plaque stage in the TgCRND8 mouse model of Alzheimer's disease.

Cavanagh C, Colby-Milley J, Bouvier D, Farso M, Chabot JG, Quirion R, Krantic S.

J Alzheimers Dis. 2013;36(2):233-8. doi: 10.3233/JAD-122131.

PMID:
23579326
2.

Inflammation occurs early during the Abeta deposition process in TgCRND8 mice.

Dudal S, Krzywkowski P, Paquette J, Morissette C, Lacombe D, Tremblay P, Gervais F.

Neurobiol Aging. 2004 Aug;25(7):861-71.

PMID:
15212840
3.

Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic.

Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, Ruano D, Vizuete M, Gutierrez A, Vitorica J.

J Neurosci. 2008 Nov 5;28(45):11650-61. doi: 10.1523/JNEUROSCI.3024-08.2008.

4.

Aβ plaque-associated glial reaction as a determinant of apoptotic neuronal death and cortical gliogenesis: a study in APP mutant mice.

Luccarini I, Grossi C, Traini C, Fiorentini A, Ed Dami T, Casamenti F.

Neurosci Lett. 2012 Jan 6;506(1):94-9. doi: 10.1016/j.neulet.2011.10.056. Epub 2011 Oct 26.

PMID:
22056484
5.

Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.

Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, Knuesel I.

J Neurosci. 2010 Jul 7;30(27):9228-40. doi: 10.1523/JNEUROSCI.0418-10.2010.

6.

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ.

J Neurosci. 2012 Jul 11;32(28):9677-89. doi: 10.1523/JNEUROSCI.4742-11.2012.

7.

All-trans retinoic acid improved impaired proliferation of neural stem cells and suppressed microglial activation in the hippocampus in an Alzheimer's mouse model.

Takamura R, Watamura N, Nikkuni M, Ohshima T.

J Neurosci Res. 2017 Mar;95(3):897-906. doi: 10.1002/jnr.23843. Epub 2016 Jul 22.

PMID:
27448243
8.

Microglial VEGF receptor response is an integral chemotactic component in Alzheimer's disease pathology.

Ryu JK, Cho T, Choi HB, Wang YT, McLarnon JG.

J Neurosci. 2009 Jan 7;29(1):3-13. doi: 10.1523/JNEUROSCI.2888-08.2009.

9.

Quantitative proteomic analysis of the hippocampus in the 5XFAD mouse model at early stages of Alzheimer's disease pathology.

Hong I, Kang T, Yoo Y, Park R, Lee J, Lee S, Kim J, Song B, Kim SY, Moon M, Yun KN, Kim JY, Mook-Jung I, Park YM, Choi S.

J Alzheimers Dis. 2013;36(2):321-34. doi: 10.3233/JAD-130311.

PMID:
23603400
10.

CaV1.2 calcium channel expression in reactive astrocytes is associated with the formation of amyloid-β plaques in an Alzheimer's disease mouse model.

Daschil N, Obermair GJ, Flucher BE, Stefanova N, Hutter-Paier B, Windisch M, Humpel C, Marksteiner J.

J Alzheimers Dis. 2013;37(2):439-51. doi: 10.3233/JAD-130560.

11.

Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer's disease.

Kim WS, Li H, Ruberu K, Chan S, Elliott DA, Low JK, Cheng D, Karl T, Garner B.

J Neurosci. 2013 Mar 6;33(10):4387-94. doi: 10.1523/JNEUROSCI.4165-12.2013.

12.

Transgenic mice as a model of pre-clinical Alzheimer's disease.

Ferretti MT, Partridge V, Leon WC, Canneva F, Allard S, Arvanitis DN, Vercauteren F, Houle D, Ducatenzeiler A, Klein WL, Glabe CG, Szyf M, Cuello AC.

Curr Alzheimer Res. 2011 Feb;8(1):4-23.

PMID:
21143159
13.

Metallothionein-I and -III expression in animal models of Alzheimer disease.

Carrasco J, Adlard P, Cotman C, Quintana A, Penkowa M, Xu F, Van Nostrand WE, Hidalgo J.

Neuroscience. 2006 Dec 28;143(4):911-22. Epub 2006 Oct 4.

PMID:
17027170
14.

No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease.

Hillmann A, Hahn S, Schilling S, Hoffmann T, Demuth HU, Bulic B, Schneider-Axmann T, Bayer TA, Weggen S, Wirths O.

Neurobiol Aging. 2012 Apr;33(4):833.e39-50. doi: 10.1016/j.neurobiolaging.2011.08.006. Epub 2011 Sep 22.

PMID:
21943956
15.

Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease.

Ager RR, Fonseca MI, Chu SH, Sanderson SD, Taylor SM, Woodruff TM, Tenner AJ.

J Neurochem. 2010 Apr;113(2):389-401. doi: 10.1111/j.1471-4159.2010.06595.x. Epub 2010 Feb 2.

16.

CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease.

Imbimbo BP, Giardino L, Sivilia S, Giuliani A, Gusciglio M, Pietrini V, Del Giudice E, D'Arrigo A, Leon A, Villetti G, Calzà L.

J Alzheimers Dis. 2010;20(1):159-73. doi: 10.3233/JAD-2010-1366.

PMID:
20164581
17.

Telomere shortening reduces Alzheimer's disease amyloid pathology in mice.

Rolyan H, Scheffold A, Heinrich A, Begus-Nahrmann Y, Langkopf BH, Hölter SM, Vogt-Weisenhorn DM, Liss B, Wurst W, Lie DC, Thal DR, Biber K, Rudolph KL.

Brain. 2011 Jul;134(Pt 7):2044-56. doi: 10.1093/brain/awr133. Epub 2011 Jun 14.

PMID:
21672962
18.

Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology.

van Groen T, Kadish I.

Brain Res Brain Res Rev. 2005 Apr;48(2):370-8.

PMID:
15850676
19.

Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease.

Simard AR, Soulet D, Gowing G, Julien JP, Rivest S.

Neuron. 2006 Feb 16;49(4):489-502.

20.

Transgenic AD model mice, effects of potential anti-AD treatments on inflammation, and pathology.

van Groen T, Miettinen P, Kadish I.

J Alzheimers Dis. 2011;24(2):301-13. doi: 10.3233/JAD-2011-101479.

PMID:
21239852

Supplemental Content

Support Center